U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06827457) titled 'A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.' on Jan. 22.
Brief Summary: This study is designed to evaluate the safety, tolerability, PK and PD of GenSci120 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
Study Start Date: April 21
Study Type: INTERVENTIONAL
Condition:
Autoimmune Disease
Intervention:
DRUG: GenSci120
Administered SC.
DRUG: Placebo
Administered SC.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....